Pexidartinib not checked

Daiichi Sankyo · PLX3397

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
None yet
 
Trials
1 active
7 in total
Targets
FMS · KIT · FLT3
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
How it’s given
“400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)”In the company’s words, NCT04488822 on ClinicalTrials.gov
Tested for
Tenosynovial Giant Cell Tumor
Main trialPhase 3
“This study will assess pexidartinib in adult participants with symptomatic TGCT that is associated with severe morbidity or functional limitations and not amendable to improvement with surgery.”In the company’s words, NCT04488822 on ClinicalTrials.gov
Other names
TURALIO · PLX3397

Other drugs for Tenosynovial Giant Cell Tumor

All 4 drugs for Tenosynovial Giant Cell Tumor

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 27 Oct 2021 A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
Phase 4Completed 7 Jul 2023 Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Phase 3Completed 27 Mar 2017 Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
Phase 2Completed 20 Mar 2023 A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
Phase 1Completed 13 Jun 2017 Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors
Phase 1Completed 31 Jan 2018 Safety Study of PLX108-01 in Patients With Solid Tumors
Phase 1Completed 26 Sep 2018 Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pexidartinib

Following is part of Solo: you see every change to Pexidartinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in